Eureka Therapeutics

Eureka Therapeutics is a private, clinical-stage biotech company headquartered in Emeryville, California, founded in 2006. The company is advancing a pipeline of T-cell therapies for solid tumors, anchored by its two core technology platforms: the ARTEMIS T-cell receptor platform and the E-ALPHA antibody discovery platform. A key program, ECT204 for hepatocellular carcinoma, has received FDA RMAT designation, indicating significant regulatory recognition. Eureka's strategy focuses on overcoming the challenges of treating solid tumors with cell therapy, a major unmet need in oncology.

Two proprietary platforms: 1) ARTEMIS (AbTCR) - an antibody-based T-cell receptor platform for engineering T cells to target intracellular antigens presented by MHC for solid tumors. 2) E-ALPHA - a high-throughput antibody discovery platform for identifying fully human antibodies against challenging targets, including intracellular proteins.

Eureka competes in the crowded and rapidly evolving field of cell therapy for solid tumors, facing competition from other biotechs developing TCR-T therapies, next-gen CAR-Ts (e.g., with logic gates or armored constructs), and TIL therapies. Large pharmaceutical companies with major oncology divisions are also active in this space through internal pipelines and acquisitions. Eureka's differentiation lies in its ARTEMIS platform's focus on intracellular targets via an AbTCR approach.